NCT03685084View on ClinicalTrials.gov

Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

October 10, 2013

Primary Completion Date

January 13, 2014

Study Completion Date

January 13, 2014

Conditions

Healthy

Interventions

DRUG

AAI101 i.v.

600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)

DRUG

Saline 0.9% infusion

Vehicle infusion

DRUG

Piperacillin i.v.

piperacillin 3 g i.v.

DRUG

Cefepime i.v.

cefepime 1 g i.v.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Allecra

INDUSTRY